These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36074989)

  • 1. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials.
    Cordero A; Nuñez J; Bertomeu-González V; Fácila L; Quintanilla MA; Rodríguez-Mañero M; Escribano D; Valle A; de la Espriella R; Torres-Llergo J; Bayés-Genís A; González-Juanatey JR
    Am J Ther; 2022 Sep-Oct 01; 29(5):e572-e575. PubMed ID: 36074989
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Lin J; Zhou J; Xie G; Liu J
    Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Sacubitril/Valsartan on Right Heart Failure.
    Imamura T; Hori M; Ueno H; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):932-934. PubMed ID: 34276024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Application of Sacubitril/Valsartan in Heart Failure: Erratum.
    Am J Ther; 2022 Nov-Dec 01; 29(6):e788. PubMed ID: 36608068
    [No Abstract]   [Full Text] [Related]  

  • 8. [Update on the clinical application of valsartan/sacubitril in patients with heart failure].
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):538-541. PubMed ID: 28648033
    [No Abstract]   [Full Text] [Related]  

  • 9. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.
    Bhatt AS; Vaduganathan M; Solomon SD; Schneeweiss S; Lauffenburger JC; Desai RJ
    Eur J Heart Fail; 2022 Sep; 24(9):1506-1515. PubMed ID: 35689603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.
    Samsky MD; Sen S
    JACC Heart Fail; 2022 Jul; 10(7):457-458. PubMed ID: 35772854
    [No Abstract]   [Full Text] [Related]  

  • 13. No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
    Slawson DC
    Am Fam Physician; 2022 Jun; 105(6):Online. PubMed ID: 35704816
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
    Lozhkina NG; Spiridonov AN
    Kardiologiia; 2022 May; 62(5):72-74. PubMed ID: 35692177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series.
    Figueiredo CS; de Melo RMV; Viana TT; de Jesus AGQ; da Silva TC; da Silva VM; de Carvalho WN; da Silva DNV; Passos LCS
    Br J Clin Pharmacol; 2022 Feb; 88(2):429-436. PubMed ID: 34240468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.
    Cheng S; Zhang N; Hua W
    Am J Cardiovasc Drugs; 2021 Jul; 21(4):383-393. PubMed ID: 33118151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good.
    Álvarez-García J
    Eur J Heart Fail; 2022 Sep; 24(9):1516-1518. PubMed ID: 35869745
    [No Abstract]   [Full Text] [Related]  

  • 19. Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    Butt JH; McMurray JJV
    Eur J Heart Fail; 2022 Sep; 24(9):1623-1624. PubMed ID: 35919944
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.